Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0025362 (
mental retardation
)
15,878
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Trisomy of the whole or distal part of human chromosome 21 (
HSA
21) (Ts21) results in Down Syndrome (DS), which is characterized in part by
mental retardation
and associated neurological abnormalities. Structural abnormalities observed frequently include reduced brain weight, decreased number and depth of sulci in the cerebral cortices, neuronal heterotopias, and reduced numbers of specific populations of neurons, such as granule cells, in the cerebral cortices. Abnormalities in the structure of cells, primarily of the dendrites, are observed in portions of the neuraxis, such as the hippocampus, cerebellum, and cerebral cortices. Functional abnormalities in membrane properties in peripheral structures and in neurotransmitter enzyme systems in both peripheral and central structures are observed also. Brains of DS individuals over the age of 40 exhibit the characteristic neuropathologic and neurochemical stigmata of Alzheimer's disease (AD). The cholinergic and noradrenergic systems appear to be particularly vulnerable. To elucidate the mechanisms responsible for these abnormalities, identification of the genes located in the distal part of
HSA
21 and the systematic study of animal model systems with close genetic homology are essential.
...
PMID:The neurobiologic consequences of Down syndrome. 287 70
Some descriptive results from a survey of Virginia hospitals regarding their planning capacities have been presented. The results are the generation of four hypotheses about hospital planning structures and hospital-
HSA
relationships. No attempts to posit causality have been made. In summary, it can be stated that there is a need for subsequent research into the extent to which
HSA
and P.L. 93-641 have affected change in health care facilities. Future research might examine the four hypotheses as applied to hospitals. Additionally, subsequent research efforts should address the extent to which organizational change within other types of health care facilities has occurred since P.L. 93-641 was enacted. In particular, community health delivery systems, such as mental health and
mental retardation
programs, family planning agencies, and medical group practices, might be examined in order to determine their capacity to do planning in its relationship to the passage of this Act.
...
PMID:Hospital planning in Virginia after P.L. 93-641. 645 Jan 66
Deletions within
HSA
band 4p16.3 cause Wolf-Hirschhorn syndrome (WHS), which comprises
mental retardation
and developmental defects. A WHS critical region (WHSCR) of approximately 165 kb has been defined on the basis of 2 atypical interstitial deletions; however, genotype-phenotype correlation remains controversial, due to the large size of deletion usually involving several megabases. We report on the first known patient with a small de novo interstitial deletion restricted to the WHSCR who presented with a partial WHS phenotype consisting only of low body weight for height, speech delay, and minor facial anomalies; shortness of stature, microcephaly, seizures and
mental retardation
were absent. The deletion was initially demonstrated by FISH analysis, and breakpoints were narrowed with a "mini-FISH" technique using 3-5 kb amplicons. A breakpoint-spanning PCR assay defined the distal breakpoint as disrupting the WHSC1 gene within intron 5, exactly after an AluJb repeat. The proximal breakpoint was not found to be associated with a repeated sequence or a known gene. The deletion encompasses 191.5 kb and includes WHSC2, but not LETM1. Thus, manifestations attributable to this deletion are reduced weight for height, minor facial anomalies, ADHD and some learning and fine motor deficiencies, while seizures may be associated with deletions of LETM1.
...
PMID:First known microdeletion within the Wolf-Hirschhorn syndrome critical region refines genotype-phenotype correlation. 1125 5
Down's syndrome (DS) in humans is caused by trisomy of chromosome 21 (
HSA
21). DS patients have a variety of pathologies, including
mental retardation
and an unusually high incidence of leukemia or lymphoma such as megakaryocytic leukemia. Individuals with DS develop the characteristic neuropathological hallmarks of Alzheimer's disease (AD) in early adulthood, generally by the fourth decade of life. There are several mouse models of DS that have a segmental trisomy of mouse chromosome 16 (MMU 16) with triplicated genes orthologous to
HSA
21. These mice display neurodegeneration similar to DS. Although brain pathology in DS models is known, little information is available about other organs. We studied the extraneural pathology in aged DS mice (Ts65Dn, Ts2 and Ts1Cje aged 8 to 24 months) as well as other mouse models of neurodegeneration, including presenilin (PS), amyloid-beta precursor protein (APP), and tau (hTau and JNPL) transgenic mice. An increased incidence of peripheral amyloidosis, positive for amyloid A (AA) but not amyloid-beta peptide (A beta), was found in APP over-expressing and tauopathic mice as compared to non-transgenic (ntg) littermates or to DS mouse models. A higher incidence of lymphoma was found in the DS models, including Ts1Cje that is trisomic for a small segment of MMU 16 not including the App gene, but not in the APP over-expressing mice, suggesting that high APP expression is not the cause of lymphoma in DS. The occurrence of lymphomas in mouse DS models is of interest in relation to the increased incidence of malignant conditions in human DS.
...
PMID:Systemic pathology in aged mouse models of Down's syndrome and Alzheimer's disease. 1904 4